{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:40:12Z","timestamp":1782744012033,"version":"3.54.5"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1097\/ico.0b013e31817786ad","type":"journal-article","created":{"date-parts":[[2008,9,19]],"date-time":"2008-09-19T07:15:20Z","timestamp":1221808520000},"page":"992-995","source":"Crossref","is-referenced-by-count":62,"title":["Subconjunctival Bevacizumab for Corneal Neovascularization"],"prefix":"10.1097","volume":"27","author":[{"given":"Priyanka P","family":"Doctor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja V","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Stephen","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210204","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00003226-198706040-00004","article-title":"Corneal neovascularization: pathogenesis and inhibition.","volume":"6","author":"Epstein","year":"1987","journal-title":"Cornea"},{"key":"R2-5-20210204","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm0195-27","article-title":"Angiogenesis in cancer, vascular, rheumatoid and other disease.","volume":"1","author":"Folkman","year":"1995","journal-title":"Nat Med"},{"key":"R3-5-20210204","first-page":"18","article-title":"Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization.","volume":"39","author":"Amano","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R4-5-20210204","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1006\/exer.1999.0790","article-title":"Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation associated corneal neovascularization.","volume":"70","author":"Kvanta","year":"2000","journal-title":"Exp Eye Res"},{"key":"R5-5-20210204","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1600-0420.2004.00312.x","article-title":"Vascular endothelium growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing.","volume":"82","author":"Gan","year":"2004","journal-title":"Acta Ophthalmol Scand"},{"key":"R6-5-20210204","first-page":"1112","article-title":"Correlation of VEGF expression by leukocytes with the growth and regression of blood vessels in the rat cornea.","volume":"40","author":"Edelman","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R7-5-20210204","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1126\/science.2416056","article-title":"A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment.","volume":"230","author":"Crum","year":"1985","journal-title":"Science"},{"key":"R8-5-20210204","first-page":"1588","article-title":"Effects of inhibitors of arachidonic acid metabolism on corneal neovascularization in the rat.","volume":"30","author":"Haynes","year":"1989","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R9-5-20210204","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","article-title":"Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.","volume":"333","author":"Ferrara","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"R11-5-20210204","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"R12-5-20210204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2006.02.037","article-title":"Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.","volume":"142","author":"Bashshur","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R13-5-20210204","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"R14-5-20210204","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/ICO.0b013e3180de1d0a","article-title":"Safety profile of bevacizumab on cultured human corneal cells.","volume":"26","author":"Yoeruek","year":"2007","journal-title":"Cornea"},{"key":"R15-5-20210204","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/archopht.125.6.834","article-title":"Topical bevacizumab therapy for corneal neovascularization.","volume":"125","author":"DeStafeno","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"R16-5-20210204","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00417-007-0587-4","article-title":"Subconjunctival bevacizumab for corneal neovascularization.","volume":"245","author":"Erdurmus","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R17-5-20210204","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3109\/02713688809031785","article-title":"Modulation of immunogenic keratitis in rabbits by topical administration of inhibitors of lipoxygenase and cyclooxygenase.","volume":"7","author":"Verbey","year":"1988","journal-title":"Curr Eye Res"},{"key":"R18-5-20210204","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1006\/exer.1998.0512","article-title":"The heparan sulfate suleparoide inhibits rat corneal angiogenesis and in vitro neovascularization.","volume":"67","author":"Benelli","year":"1998","journal-title":"Exp Eye Res"},{"key":"R19-5-20210204","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s004170050387","article-title":"Topical application of methotrexate for inhibition of corneal angiogenesis.","volume":"237","author":"Joussen","year":"1999","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R20-5-20210204","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/archopht.1992.01080150103037","article-title":"Suppression of corneal neovascularization with cyclosporine.","volume":"110","author":"Lipman","year":"1992","journal-title":"Arch Ophthalmol"},{"key":"R21-5-20210204","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis.","volume":"91","author":"DAmato","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"R22-5-20210204","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjo.2006.107912","article-title":"Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin).","volume":"91","author":"Roberta","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R23-5-20210204","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00417-007-0587-4","article-title":"Subconjunctival bevacizumab for corneal neovascularization.","volume":"245","author":"Erdurmus","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R24-5-20210204","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","article-title":"Corneal neovascularization.","volume":"12","author":"Chang","year":"2001","journal-title":"Curr Opin Ophthalmol"},{"key":"R25-5-20210204","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/00003226-200007000-00025","article-title":"Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor and transforming growth factor in human corneas with neovascularization.","volume":"19","author":"Cursiefen","year":"2000","journal-title":"Cornea"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0b013e31817786ad","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T19:28:38Z","timestamp":1621884518000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003226-200810000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e31817786ad","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}